NanI Sialidase Enhances the Action of Clostridium perfringens Enterotoxin in the Presence of Mucus.


Journal

mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533

Informations de publication

Date de publication:
22 12 2021
Historique:
pubmed: 16 12 2021
medline: 12 2 2022
entrez: 15 12 2021
Statut: ppublish

Résumé

Clostridium perfringens enterotoxin (CPE) is the main virulence factor for C. perfringens type F strains to cause human gastrointestinal diseases, which can involve lethal enterotoxemia. During type F disease, CPE encounters an adherent mucus layer overlying the intestines, so the current study evaluated if NanI potentiates CPE activity in the presence of adherent mucus. CPE alone caused more cytotoxicity transepithelial electrical resistance (TEER) and permeability to fluorescent dextran (FD) for minimal mucus-producing HT29 cells versus that in their derivative HT29-MTX-E12 cells, which produce abundant adherent mucus. However, for HT29-MTX-E12 cells, the presence of NanI significantly increased CPE binding and pore formation, which enhanced their sensitivity to CPE effects on cytotoxicity, TEER, and FD permeability. When the ability of NanI to potentiate CPE-induced enterotoxemia was then tested in a mouse small intestinal loop enterotoxemia model, a pathophysiologically relevant 50 μg/mL dose of CPE did not kill mice. However, the copresence of purified NanI resulted in significant CPE-induced lethality. More CPE was detected in the sera of mice challenged with 50 μg/mL of CPE when NanI was copresent during challenge. The copresence of NanI and CPE during challenge also significantly increased intestinal histologic damage compared to that after challenge with CPE alone, suggesting that NanI enhancement of CPE-induced intestinal damage may increase CPE absorption into blood. Overall, these results indicate that (i) mucus inhibits CPE action and (ii) NanI can potentiate CPE action in the presence of mucus, which may help explain why type F strains that produce relatively low levels of CPE are still pathogenic.

Identifiants

pubmed: 34908460
doi: 10.1128/mSphere.00848-21
pmc: PMC8673254
doi:

Substances chimiques

Enterotoxins 0
Virulence Factors 0
enterotoxin, Clostridium 0
Neuraminidase EC 3.2.1.18

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0084821

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI140010
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI148911
Pays : United States

Références

Infect Immun. 2003 Aug;71(8):4260-70
pubmed: 12874301
Infect Immun. 2014 Nov;82(11):4620-30
pubmed: 25135687
Infect Immun. 2007 May;75(5):2381-90
pubmed: 17307943
PLoS Pathog. 2011 Dec;7(12):e1002429
pubmed: 22174687
Virulence. 2021 Dec;12(1):723-753
pubmed: 33843463
Infect Immun. 2018 Nov 20;86(12):
pubmed: 30297524
J Clin Pathol. 1985 Feb;38(2):222-8
pubmed: 2857184
Infect Immun. 2011 Aug;79(8):3020-7
pubmed: 21628512
Anaerobe. 2018 Oct;53:5-10
pubmed: 29866424
Future Microbiol. 2014;9(3):361-77
pubmed: 24762309
Infect Immun. 2008 Aug;76(8):3793-800
pubmed: 18505809
BMC Cell Biol. 2006 May 02;7:20
pubmed: 16670004
Int J Mol Sci. 2018 Sep 07;19(9):
pubmed: 30205533
S Afr J Psychiatr. 2019 Aug 26;25:1339
pubmed: 32201630
Microbiol Spectr. 2015 Aug;3(4):
pubmed: 26350327
Cell Microbiol. 2005 Jan;7(1):129-46
pubmed: 15617529
Gastroenterol Rep (Oxf). 2019 Feb;7(1):3-12
pubmed: 30792861
Appl Environ Microbiol. 2014 Mar;80(5):1701-9
pubmed: 24375134
mBio. 2019 Dec 17;10(6):
pubmed: 31848291
Infect Immun. 2021 Oct 15;89(11):e0025621
pubmed: 34424746
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337447
Infect Immun. 2018 Jan 22;86(2):
pubmed: 29203541
Infect Immun. 1999 Nov;67(11):5634-41
pubmed: 10531210
Toxins (Basel). 2016 Mar 16;8(3):
pubmed: 26999202
Mol Microbiol. 1999 Sep;33(5):946-58
pubmed: 10476029
Infect Immun. 2017 Dec 19;86(1):
pubmed: 29038129
MMWR Morb Mortal Wkly Rep. 2012 Aug 17;61(32):605-8
pubmed: 22895383
Infect Immun. 2009 Oct;77(10):4421-8
pubmed: 19651873
J Biol Chem. 2000 Jun 16;275(24):18407-17
pubmed: 10749869
Infect Immun. 2018 Jun 21;86(7):
pubmed: 29685988
J Biol Chem. 2011 Jun 3;286(22):19549-55
pubmed: 21489981
Anaerobe. 1998 Apr;4(2):69-79
pubmed: 16887625
Biochem Soc Trans. 2016 Feb;44(1):166-75
pubmed: 26862202
Cell Microbiol. 2007 Nov;9(11):2734-55
pubmed: 17587331
Methods Enzymol. 1988;165:94-103
pubmed: 2906731
Trends Microbiol. 2016 Jun;24(6):463-476
pubmed: 26897710
Front Genet. 2015 Mar 19;6:81
pubmed: 25852737
Gut. 2020 Dec;69(12):2232-2243
pubmed: 32917747
Toxins (Basel). 2019 Oct 09;11(10):
pubmed: 31601044
J Mol Biol. 2011 Oct 14;413(1):138-49
pubmed: 21839091
Toxins (Basel). 2016 Nov 19;8(11):
pubmed: 27869757
Pharm Res. 2001 Aug;18(8):1138-45
pubmed: 11587485
Clin Infect Dis. 2005 May 15;40(10):e78-83
pubmed: 15844055

Auteurs

Mauricio A Navarro (MA)

California Animal Health and Food Safety Laboratory System, School of Veterinary Medicine, University of California, Davisgrid.27860.3b, San Bernardino, California, USA.
Instituto de Patología Animal, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia, Chile.

Jihong Li (J)

Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Juliann Beingesser (J)

California Animal Health and Food Safety Laboratory System, School of Veterinary Medicine, University of California, Davisgrid.27860.3b, San Bernardino, California, USA.

Bruce A McClane (BA)

Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Francisco A Uzal (FA)

California Animal Health and Food Safety Laboratory System, School of Veterinary Medicine, University of California, Davisgrid.27860.3b, San Bernardino, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH